Potential conflict of interest: KMT is CEO of Antipodean Pharmaceuticals. BJS, MPM, and RAJS are consultants and scientific advisors to Antipodean Pharmaceuticals. MPM and RAJS have a share of the ownership of IP being developed by Antipodean Pharmaceuticals.
A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease
Article first published online: 21 JUN 2010
Copyright © 2010 Movement Disorder Society
Volume 25, Issue 11, pages 1670–1674, 15 August 2010
How to Cite
Snow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J. D., Fung, V., Smith, R. A.J., Murphy, M. P. and Taylor, K. M. (2010), A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson's disease. Mov. Disord., 25: 1670–1674. doi: 10.1002/mds.23148
- Issue published online: 18 AUG 2010
- Article first published online: 21 JUN 2010
- Manuscript Accepted: 15 MAR 2010
- Manuscript Revised: 8 DEC 2009
- Manuscript Received: 10 SEP 2009
- Antipodean Pharmaceuticals Inc.
- oxidative damage;
Multiple lines of evidence point to mitochondrial oxidative stress as a potential pathogenic cause for Parkinson's disease (PD). MitoQ is a powerful mitochondrial antioxidant. It is absorbed orally and concentrates within mitochondria where it has been shown to protect against oxidative damage. We enrolled 128 newly diagnosed untreated patients with PD in a double-blind study of two doses of MitoQ compared with placebo to explore the hypothesis that, over 12 months, MitoQ would slow the progression of PD as measured by clinical scores, particularly the Unified Parkinson Disease Rating Scale. We showed no difference between MitoQ and placebo on any measure of PD progression. MitoQ does not slow the progression of PD, and this finding should be taken into account when considering the oxidative stress hypothesis for the pathogenesis of PD. © 2010 Movement Disorder Society